Literature DB >> 11791127

Resistant mechanisms of anthracyclines--pirarubicin might partly break through the P-glycoprotein-mediated drug-resistance of human breast cancer tissues.

T Kubota1, T Furukawa, H Tanino, A Suto, Y Otan, M Watanabe, T Ikeda, M Kitajima.   

Abstract

Juliano and Ling initially reported the expression of a 170 kDa glycoprotein in the membrane of Chinese hamster ovarian cells in 1976, and named this glycoprotein P-glycoprotein (P-gp) based on its predicted role of causing "permeability" of the cell membrane. After much research on anthracycline-resistance, this P-gp was finally characterized as a multidrug-resistant protein coded by the mdr1 gene. Multidrug resistance associated protein (MRP) was initially cloned from H69AR, a human small cell-lung carcinoma cell line which is resistant to doxorubicin (DXR) but does not express P-gp. MRP also excretes substrates through the cell membrane using energy from ATP catabolism. The substrate of MRP is conjugated with glutathione before active efflux from cell membrane. Recently, membrane transporter proteins were re-categorized as members of "ATP-Binding Cassette transporter"(ABC-transporter) superfamily, as shown at http://www.med.rug.nl/mdl/humanabc.htm and http://www.gene.ucl.ac.uk/nomenclature/genefamily/abc.html. A total of ABC transporters have been defined, and MDR1 and multidrug resistance associated protein 1 (MRP1) were reclassified as ABCB1 and ABCC1, respectively. Their associated superfamilies include 11 and 13 other protein, in addition to ABCB and ABCC, respectively. Lung resistance-related protein (LRP) is not a member of the superfamily of ABC transporter proteins, because it shows nuclear membrane expression and transports substrate between nucleus and cytoplasm. LRP was initially cloned from a non-small cell lung carcinoma cell line, SW1573/2R120 which is resistant to DXR, vincristine, etoposide and gramicidin D and does not express P-gp. The mechanisms of resistance remains unclear, and why some resistant cell lines express P-gp and others express MRP and/or LRP is likewise unclear.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11791127     DOI: 10.1007/bf02967534

Source DB:  PubMed          Journal:  Breast Cancer        ISSN: 1340-6868            Impact factor:   4.239


  7 in total

1.  Drug sensitivity and drug resistance profiles of human intrahepatic cholangiocarcinoma cell lines.

Authors:  Nisana Tepsiri; Liengchai Chaturat; Banchob Sripa; Wises Namwat; Sopit Wongkham; Vajarabhongsa Bhudhisawasdi; Wichittra Tassaneeyakul
Journal:  World J Gastroenterol       Date:  2005-05-14       Impact factor: 5.742

2.  Differential effects of c-myc and ABCB1 silencing on reversing drug resistance in HepG2/Dox cells.

Authors:  Shaymaa M M Yahya; Ahmed R Hamed; Mohamed Emara; Maha M Soltan; Gamal Eldein F Abd-Ellatef; Salma M Abdelnasser
Journal:  Tumour Biol       Date:  2015-11-23

3.  Lapatinib antagonizes multidrug resistance-associated protein 1-mediated multidrug resistance by inhibiting its transport function.

Authors:  Shao-lin Ma; Ya-peng Hu; Fang Wang; Zhen-cong Huang; Yi-fan Chen; Xiao-kun Wang; Li-wu Fu
Journal:  Mol Med       Date:  2014-09-08       Impact factor: 6.354

4.  Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its function.

Authors:  Chun-ling Dai; Yong-ju Liang; Li-ming Chen; Xu Zhang; Wen-jing Deng; Xiao-dong Su; Zhi Shi; Chung-pu Wu; Charles R Ashby; Shin-ichi Akiyama; Suresh V Ambudkar; Zhe-sheng Chen; Li-wu Fu
Journal:  Biochem Pharmacol       Date:  2009-05-03       Impact factor: 5.858

5.  Tumor targeting with pH-responsive poly(2-oxazoline)-based nanogels for metronomic doxorubicin treatment.

Authors:  Doerte Hoelzer; Meike N Leiske; Matthias Hartlieb; Tanja Bus; David Pretzel; Stephanie Hoeppener; Kristian Kempe; René Thierbach; Ulrich S Schubert
Journal:  Oncotarget       Date:  2018-04-27

6.  Inhibitory effect of Ubenimex combined with fluorouracil on multiple drug resistance and P-glycoprotein expression level in non-small lung cancer.

Authors:  Jun Wan; Xie-An Ling; Jian Wang; Guang-Gui Ding; Xi Wang
Journal:  J Cell Mol Med       Date:  2020-09-17       Impact factor: 5.310

7.  Modulating drug resistance by targeting BCRP/ABCG2 using retrovirus-mediated RNA interference.

Authors:  Ni Xie; Lisha Mou; Jianhui Yuan; Wenlan Liu; Tingting Deng; Zigang Li; Yi Jing; Yi Jin; Zhangli Hu
Journal:  PLoS One       Date:  2014-07-30       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.